NeurAxis, Inc. Overview
Pro stress-test →NeurAxis is a medical technology company developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company's flagship technology is Percutaneous Electrical Nerve Field Stimulation (PENFS), with its FDA-cleared IB-Stim device for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients 8 years and older.
Strategic Profile
Pro stress-test →NeurAxis demonstrated strong revenue growth of 27% in Q4 2025 to $968k and 33% for full year 2025 to $3.6M. Key commercial milestones include a Category I CPT code effective January 2026, a VA Federal Supply Schedule contract, and expanded FDA clearance for IB-Stim. The company is positioning itself as a focused player in the neuromodulation space targeting gastrointestinal disorders.
Competitive Landscape
Pro stress-test →Competitors in the neuromodulation and medical device space include Akari Therapeutics, SeaStar Medical Holding, Rein Therapeutics, Lixte Biotechnology, and Fibrobiologics. NeurAxis competes in the specialty medical device market focused on gastrointestinal disorders with a targeted platform approach.
Industry Context
NeurAxis, Inc. operates in Medical Devices & Neuromodulation.
Key facts
Founded: 2023 · Headquarters: Carmel, Indiana · Revenue: $3.6M (2025) · Market cap: N/A